SERO Serologicals (MM)

Serologicals Corporation (NASDAQ: SERO) today announced that it is scheduled to give an investor presentation at the JPMorgan Small Cap Conference on November 2, 2005. Bud Ingalls, Vice President, Finance and Chief Financial Officer for Serologicals Corporation, will be making the presentation, scheduled for 8:00 a.m. (ET) at The Four Seasons Hotel in Boston, MA. The presentation will be web cast live (audio only) and can be accessed through the Company's website at www.serologicals.com, or at http://equityconferences.jpmorgan.com. Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, GA., is a global leader in developing and commercializing consumable biological products, enabling technologies and services in support of biological research, drug discovery, and the bioprocessing of life-enhancing products. Our customers include researchers at major life science companies and leading research institutions involved in key disciplines, such as neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and stem cell research. In addition, Serologicals is the world's leading provider of monoclonal antibodies for the blood typing industry. Serologicals employs a total of more than 1,000 people worldwide in three Serologicals' companies: Chemicon International, headquartered in Temecula, California, Upstate Group, LLC, headquartered in Charlottesville, Virginia and Celliance Corporation, headquartered in Atlanta Georgia. For more information, please visit our website: www.serologicals.com.